-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152

Benzinga·10/13/2026 10:06:01
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.